Multicenter phase II trial of doxorubicin and cyclophosphamide (AC) followed by weekly docetaxel (T) as neoadjuvant treatment for operable stage II and IIIA breast cancer patients
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 20 Sep 2006 New trial record.